Intravitreal bevacizumab for traumatic choroidal rupture

Min Kim, Jin Hyung Kim, Yuri Seo, Hyoung Jun Koh, Sungchul Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To report a case of visual loss associated with traumatic choroidal rupture after blunt ocular trauma that was successfully treated with an early intravitreal bevacizumab injection despite the absence of choroidal neovascularization (CNV). Case Report: A 14-year-old boy presented with visual disturbance in his left eye after sustaining an ocular contusion 4 weeks earlier. The best-corrected visual acuity (BCVA) in the left eye was 20/50. Funduscopic examination revealed macular choroidal rupture accompanied by subretinal hemorrhage. Optical coherence tomography (OCT) showed accumulation of subretinal fluid around a disrupted retinal pigment epithelium/Bruch membrane complex extending into the juxtafoveolar area, but there was no active leakage suggestive of CNVon fluorescein angiography. Intravitreal bevacizumab (1.25 mg) injection was performed to treat persistent serous retinal detachment at macula causing visual loss. There was a reduction of subretinal fluid and concomitant improvement of BCVA to 20/30 within 1 week after intravitreal bevacizumab injection. The BCVA recovered to 20/25 in the left eye after 4 weeks, and only a minimal amount of residual fluid remained according to OCT. Complete resolution of subretinal fluid was observed by OCTat the 6-week follow-up examination, and BCVA improved to 20/20. Good visual acuity (20/20) and stable macula were maintained in the left eye at 1 year of followup without recurrence of subretinal fluid accumulation or hemorrhage and CNV. There were no ocular or systemic complications associated with intravitreal bevacizumab injection. Conclusions: Early intravitreal bevacizumab injection could be an effective treatment option for patients with vision loss associated with traumatic choroidal rupture and subretinal fluid within the posterior pole before development of CNV.

Original languageEnglish
Pages (from-to)e363-e367
JournalOptometry and Vision Science
Volume92
Issue number10
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Subretinal Fluid
Rupture
Intravitreal Injections
Visual Acuity
Choroidal Neovascularization
Optical Coherence Tomography
Bruch Membrane
Hemorrhage
Retinal Pigment Epithelium
Fluorescein Angiography
Contusions
Retinal Detachment
Bevacizumab
Recurrence
Injections
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Optometry

Cite this

Kim, Min ; Kim, Jin Hyung ; Seo, Yuri ; Koh, Hyoung Jun ; Lee, Sungchul. / Intravitreal bevacizumab for traumatic choroidal rupture. In: Optometry and Vision Science. 2015 ; Vol. 92, No. 10. pp. e363-e367.
@article{e9717036493849ffb893b1e09088515f,
title = "Intravitreal bevacizumab for traumatic choroidal rupture",
abstract = "Purpose: To report a case of visual loss associated with traumatic choroidal rupture after blunt ocular trauma that was successfully treated with an early intravitreal bevacizumab injection despite the absence of choroidal neovascularization (CNV). Case Report: A 14-year-old boy presented with visual disturbance in his left eye after sustaining an ocular contusion 4 weeks earlier. The best-corrected visual acuity (BCVA) in the left eye was 20/50. Funduscopic examination revealed macular choroidal rupture accompanied by subretinal hemorrhage. Optical coherence tomography (OCT) showed accumulation of subretinal fluid around a disrupted retinal pigment epithelium/Bruch membrane complex extending into the juxtafoveolar area, but there was no active leakage suggestive of CNVon fluorescein angiography. Intravitreal bevacizumab (1.25 mg) injection was performed to treat persistent serous retinal detachment at macula causing visual loss. There was a reduction of subretinal fluid and concomitant improvement of BCVA to 20/30 within 1 week after intravitreal bevacizumab injection. The BCVA recovered to 20/25 in the left eye after 4 weeks, and only a minimal amount of residual fluid remained according to OCT. Complete resolution of subretinal fluid was observed by OCTat the 6-week follow-up examination, and BCVA improved to 20/20. Good visual acuity (20/20) and stable macula were maintained in the left eye at 1 year of followup without recurrence of subretinal fluid accumulation or hemorrhage and CNV. There were no ocular or systemic complications associated with intravitreal bevacizumab injection. Conclusions: Early intravitreal bevacizumab injection could be an effective treatment option for patients with vision loss associated with traumatic choroidal rupture and subretinal fluid within the posterior pole before development of CNV.",
author = "Min Kim and Kim, {Jin Hyung} and Yuri Seo and Koh, {Hyoung Jun} and Sungchul Lee",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/OPX.0000000000000677",
language = "English",
volume = "92",
pages = "e363--e367",
journal = "Optometry and Vision Science",
issn = "1040-5488",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

Intravitreal bevacizumab for traumatic choroidal rupture. / Kim, Min; Kim, Jin Hyung; Seo, Yuri; Koh, Hyoung Jun; Lee, Sungchul.

In: Optometry and Vision Science, Vol. 92, No. 10, 01.10.2015, p. e363-e367.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal bevacizumab for traumatic choroidal rupture

AU - Kim, Min

AU - Kim, Jin Hyung

AU - Seo, Yuri

AU - Koh, Hyoung Jun

AU - Lee, Sungchul

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Purpose: To report a case of visual loss associated with traumatic choroidal rupture after blunt ocular trauma that was successfully treated with an early intravitreal bevacizumab injection despite the absence of choroidal neovascularization (CNV). Case Report: A 14-year-old boy presented with visual disturbance in his left eye after sustaining an ocular contusion 4 weeks earlier. The best-corrected visual acuity (BCVA) in the left eye was 20/50. Funduscopic examination revealed macular choroidal rupture accompanied by subretinal hemorrhage. Optical coherence tomography (OCT) showed accumulation of subretinal fluid around a disrupted retinal pigment epithelium/Bruch membrane complex extending into the juxtafoveolar area, but there was no active leakage suggestive of CNVon fluorescein angiography. Intravitreal bevacizumab (1.25 mg) injection was performed to treat persistent serous retinal detachment at macula causing visual loss. There was a reduction of subretinal fluid and concomitant improvement of BCVA to 20/30 within 1 week after intravitreal bevacizumab injection. The BCVA recovered to 20/25 in the left eye after 4 weeks, and only a minimal amount of residual fluid remained according to OCT. Complete resolution of subretinal fluid was observed by OCTat the 6-week follow-up examination, and BCVA improved to 20/20. Good visual acuity (20/20) and stable macula were maintained in the left eye at 1 year of followup without recurrence of subretinal fluid accumulation or hemorrhage and CNV. There were no ocular or systemic complications associated with intravitreal bevacizumab injection. Conclusions: Early intravitreal bevacizumab injection could be an effective treatment option for patients with vision loss associated with traumatic choroidal rupture and subretinal fluid within the posterior pole before development of CNV.

AB - Purpose: To report a case of visual loss associated with traumatic choroidal rupture after blunt ocular trauma that was successfully treated with an early intravitreal bevacizumab injection despite the absence of choroidal neovascularization (CNV). Case Report: A 14-year-old boy presented with visual disturbance in his left eye after sustaining an ocular contusion 4 weeks earlier. The best-corrected visual acuity (BCVA) in the left eye was 20/50. Funduscopic examination revealed macular choroidal rupture accompanied by subretinal hemorrhage. Optical coherence tomography (OCT) showed accumulation of subretinal fluid around a disrupted retinal pigment epithelium/Bruch membrane complex extending into the juxtafoveolar area, but there was no active leakage suggestive of CNVon fluorescein angiography. Intravitreal bevacizumab (1.25 mg) injection was performed to treat persistent serous retinal detachment at macula causing visual loss. There was a reduction of subretinal fluid and concomitant improvement of BCVA to 20/30 within 1 week after intravitreal bevacizumab injection. The BCVA recovered to 20/25 in the left eye after 4 weeks, and only a minimal amount of residual fluid remained according to OCT. Complete resolution of subretinal fluid was observed by OCTat the 6-week follow-up examination, and BCVA improved to 20/20. Good visual acuity (20/20) and stable macula were maintained in the left eye at 1 year of followup without recurrence of subretinal fluid accumulation or hemorrhage and CNV. There were no ocular or systemic complications associated with intravitreal bevacizumab injection. Conclusions: Early intravitreal bevacizumab injection could be an effective treatment option for patients with vision loss associated with traumatic choroidal rupture and subretinal fluid within the posterior pole before development of CNV.

UR - http://www.scopus.com/inward/record.url?scp=84942578023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942578023&partnerID=8YFLogxK

U2 - 10.1097/OPX.0000000000000677

DO - 10.1097/OPX.0000000000000677

M3 - Article

C2 - 26367340

AN - SCOPUS:84942578023

VL - 92

SP - e363-e367

JO - Optometry and Vision Science

JF - Optometry and Vision Science

SN - 1040-5488

IS - 10

ER -